相关实验视频

Updated: May 1, 2026

Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography

Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography

Published on: April 4, 2012

肥胖和瘦瘦的鲁川猪的微生物和代谢分析:对表型分歧的含义

Lihui Zhu¹, Shengwei Ma², Chuan He²

¹Institute of Animal Husbandry and Veterinary Science, Shanghai Academy of Agricultural Sciences, Shanghai 201106, China.

Animals : an open access journal from MDPI

|July 27, 2024

概括

肠道微生物和新陈代谢对卢chuan猪的明显肥胖和瘦身表型产生影响. 微生物和代谢物变化与这些猪的体重和胸围差异有关.

科学领域:

动物科学动物科学
微生物学微生物学
代谢学代谢学代谢学

背景情况:

卢chuan (LC) 猪是一种中国品种,其肉质和生殖能力优越,但生长缓慢.
控制繁殖导致了两个不同的表型:肥胖 (FLC) 和瘦 (LLC) LC猪.
宿主表型差异化越来越多地与微生物社区组成有关.

研究的目的:

为了研究FLC和LLC猪的便微生物群概况和血清代谢物.
探索肠道微生物组,代谢组和LC猪的表型分歧之间的关系.

主要方法:

使用16S rRNA测序对便微生物群组成进行分析.
使用非向代谢组学方法对血清代谢物进行分析.
微生物种群,代谢物和表型特征之间的相关性分析.

主要成果:

与LLC猪相比,FLC猪的体重,胸围和肝酶活性都较高.
在肠道微生物系中观察到显著的差异,FLC猪具有较低的*Fusobacterium*和*Streptococcus*,但较高的*Firmicutes*,*Lactobacillus*,*Phascolartobacterium*和*Rikenellaceae*_RC9_gut_group.
确定了52种改变的血清代谢物,这些代谢物参与了诸如益生素信号传递和卵细胞半转化等途径.
在FLC猪中,*Jeotgalicoccus*的丰度与体重和胸围有正相关.

结论:

肠道微生物群和代谢组在LC猪的表型差异化中扮演着至关重要的角色,将其分为肥胖和瘦肉类型.
特定的微生物种群和代谢物与体重和其他生理参数的变化有显著联系.
这项研究强调了肠道微生物组和代谢组在塑造宿主表型中的新奇相互作用.

关键词:

在SCFAs中,SCFAs是最重要的.我们的肠道微生物组.代谢生物组的代谢生物组表型差异化差异化表型差异化

更多相关视频

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

The MPLEx Protocol for Multi-omic Analyses of Soil Samples

The MPLEx Protocol for Multi-omic Analyses of Soil Samples

Published on: May 30, 2018

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...